Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,16151471,t(1/2),The t(1/2) was 26 hours (range 10 to 50).,Single-dose darbepoetin administration to anemic preterm neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16151471/),h,26,22171,DB00012,Darbepoetin alfa
,16151471,biovailability-normalized clearance,The biovailability-normalized clearance was 19 ml/hour/kg (range 5 to 54).,Single-dose darbepoetin administration to anemic preterm neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16151471/),[ml] / [h·kg],19,22172,DB00012,Darbepoetin alfa
,12426518,terminal half-life,"At week 12, the terminal half-life was 23.4 hours with darbepoetin alfa once weekly, 18.3 hours with darbepoetin alfa 3 times weekly, and 8.0 hours with epoetin 3 times weekly.",Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426518/),h,23.4,35166,DB00012,Darbepoetin alfa
,12426518,terminal half-life,"At week 12, the terminal half-life was 23.4 hours with darbepoetin alfa once weekly, 18.3 hours with darbepoetin alfa 3 times weekly, and 8.0 hours with epoetin 3 times weekly.",Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426518/),h,18.3,35167,DB00012,Darbepoetin alfa
,12426518,terminal half-life,"At week 12, the terminal half-life was 23.4 hours with darbepoetin alfa once weekly, 18.3 hours with darbepoetin alfa 3 times weekly, and 8.0 hours with epoetin 3 times weekly.",Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12426518/),h,8.0,35168,DB00012,Darbepoetin alfa
,15070102,relative bioavailability,"After a single injection, darbepoetin alfa was detected in serum through 4 weeks for all microsphere formulations tested in vivo, although relative bioavailability was higher for spray-freeze drying (28%) compared with spray drying (21%; p = 0.08) as were yields (73-82% vs. 34-57%, respectively).",Poly(lactide-co-glycolide) microsphere formulations of darbepoetin alfa: spray drying is an alternative to encapsulation by spray-freeze drying. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15070102/),%,28,35491,DB00012,Darbepoetin alfa
,15070102,relative bioavailability,"After a single injection, darbepoetin alfa was detected in serum through 4 weeks for all microsphere formulations tested in vivo, although relative bioavailability was higher for spray-freeze drying (28%) compared with spray drying (21%; p = 0.08) as were yields (73-82% vs. 34-57%, respectively).",Poly(lactide-co-glycolide) microsphere formulations of darbepoetin alfa: spray drying is an alternative to encapsulation by spray-freeze drying. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15070102/),%,21,35492,DB00012,Darbepoetin alfa
,15070102,relative bioavailability,"After a single injection, darbepoetin alfa was detected in serum through 4 weeks for all microsphere formulations tested in vivo, although relative bioavailability was higher for spray-freeze drying (28%) compared with spray drying (21%; p = 0.08) as were yields (73-82% vs. 34-57%, respectively).",Poly(lactide-co-glycolide) microsphere formulations of darbepoetin alfa: spray drying is an alternative to encapsulation by spray-freeze drying. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15070102/),%,73-82,35493,DB00012,Darbepoetin alfa
,15070102,relative bioavailability,"After a single injection, darbepoetin alfa was detected in serum through 4 weeks for all microsphere formulations tested in vivo, although relative bioavailability was higher for spray-freeze drying (28%) compared with spray drying (21%; p = 0.08) as were yields (73-82% vs. 34-57%, respectively).",Poly(lactide-co-glycolide) microsphere formulations of darbepoetin alfa: spray drying is an alternative to encapsulation by spray-freeze drying. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15070102/),%,34-57,35494,DB00012,Darbepoetin alfa
,15070102,yields,"After a single injection, darbepoetin alfa was detected in serum through 4 weeks for all microsphere formulations tested in vivo, although relative bioavailability was higher for spray-freeze drying (28%) compared with spray drying (21%; p = 0.08) as were yields (73-82% vs. 34-57%, respectively).",Poly(lactide-co-glycolide) microsphere formulations of darbepoetin alfa: spray drying is an alternative to encapsulation by spray-freeze drying. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15070102/),%,73-82,35495,DB00012,Darbepoetin alfa
,15070102,yields,"After a single injection, darbepoetin alfa was detected in serum through 4 weeks for all microsphere formulations tested in vivo, although relative bioavailability was higher for spray-freeze drying (28%) compared with spray drying (21%; p = 0.08) as were yields (73-82% vs. 34-57%, respectively).",Poly(lactide-co-glycolide) microsphere formulations of darbepoetin alfa: spray drying is an alternative to encapsulation by spray-freeze drying. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15070102/),%,34-57,35496,DB00012,Darbepoetin alfa
,16945116,CL,"The typical values of CL and V(1) were 0.0807 l h(-1) and 2.51 l, respectively.",Population pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16945116/),[l] / [h],0.0807,36478,DB00012,Darbepoetin alfa
,16945116,V(1),"The typical values of CL and V(1) were 0.0807 l h(-1) and 2.51 l, respectively.",Population pharmacokinetics of darbepoetin alfa in haemodialysis and peritoneal dialysis patients after intravenous administration. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16945116/),l,2.51,36479,DB00012,Darbepoetin alfa
,20881221,Absolute bioavailability,"Absolute bioavailability, total mean absorption time, clearance, and volume of distribution were estimated to be 44%, 52 h, 3.4 L/d/70 kg, and 5.9 L/70 kg, respectively.",Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20881221/),%,44,37390,DB00012,Darbepoetin alfa
,20881221,total mean absorption time,"Absolute bioavailability, total mean absorption time, clearance, and volume of distribution were estimated to be 44%, 52 h, 3.4 L/d/70 kg, and 5.9 L/70 kg, respectively.",Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20881221/),h,52,37391,DB00012,Darbepoetin alfa
,20881221,total mean absorption time,"Absolute bioavailability, total mean absorption time, clearance, and volume of distribution were estimated to be 44%, 52 h, 3.4 L/d/70 kg, and 5.9 L/70 kg, respectively.",Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20881221/),[l] / [70·d·kg],3.4,37392,DB00012,Darbepoetin alfa
,20881221,clearance,"Absolute bioavailability, total mean absorption time, clearance, and volume of distribution were estimated to be 44%, 52 h, 3.4 L/d/70 kg, and 5.9 L/70 kg, respectively.",Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20881221/),h,52,37393,DB00012,Darbepoetin alfa
,20881221,volume of distribution,"Absolute bioavailability, total mean absorption time, clearance, and volume of distribution were estimated to be 44%, 52 h, 3.4 L/d/70 kg, and 5.9 L/70 kg, respectively.",Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20881221/),[l] / [70·kg],5.9,37394,DB00012,Darbepoetin alfa
,20881221,pot,"The estimates of drug potency, efficacy, and RBC life span were 0.41 ng/mL, 64%, and 77 days, respectively.",Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20881221/),[ng] / [ml],0.41,37395,DB00012,Darbepoetin alfa
,20881221,efficacy,"The estimates of drug potency, efficacy, and RBC life span were 0.41 ng/mL, 64%, and 77 days, respectively.",Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20881221/),%,64,37396,DB00012,Darbepoetin alfa
,20881221,efficacy,"The estimates of drug potency, efficacy, and RBC life span were 0.41 ng/mL, 64%, and 77 days, respectively.",Exposure-response modeling of darbepoetin alfa in anemic patients with chronic kidney disease not receiving dialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20881221/),d,77,37397,DB00012,Darbepoetin alfa
,16951999,bioavailability,The bioavailability was virtually complete following SC injection into the interdigital space (88.4 +/- 15.7%).,The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16951999/),%,88.4,49610,DB00012,Darbepoetin alfa
,28189627,clearance of Darbe,The clearance of Darbe was estimated to be 0.050 L/h/kg in male infants and 0.031 L/h/kg in female infants.,Population Pharmacokinetics of Darbepoetin in Infants Following Single Intravenous and Subcutaneous Dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28189627/),[l] / [h·kg],0.050,57732,DB00012,Darbepoetin alfa
,28189627,clearance of Darbe,The clearance of Darbe was estimated to be 0.050 L/h/kg in male infants and 0.031 L/h/kg in female infants.,Population Pharmacokinetics of Darbepoetin in Infants Following Single Intravenous and Subcutaneous Dosing. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28189627/),[l] / [h·kg],0.031,57733,DB00012,Darbepoetin alfa
,28189627,Vp,"The predicted population mean value of Vp is 0.84 L/kg, which is associated with the subject's bodyweight (p < 0.05).",Population Pharmacokinetics of Darbepoetin in Infants Following Single Intravenous and Subcutaneous Dosing. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28189627/),[l] / [kg],0.84,57734,DB00012,Darbepoetin alfa
,28189627,"absorption rate (i.e., ka)","Following s.c. administration, the estimated absorption rate (i.e., ka) of Darbe was 0.062 L/h.",Population Pharmacokinetics of Darbepoetin in Infants Following Single Intravenous and Subcutaneous Dosing. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28189627/),[l] / [h],0.062,57735,DB00012,Darbepoetin alfa
,18807251,CL/f,"The typical values of CL/f, V(1)/f, and absorption rate constant were 0.158 l/h, 13.7 l, and 0.0376/h, respectively.",Population pharmacokinetics of darbepoetin alpha in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18807251/),[l] / [h],0.158,63372,DB00012,Darbepoetin alfa
,18807251,V(1)/f,"The typical values of CL/f, V(1)/f, and absorption rate constant were 0.158 l/h, 13.7 l, and 0.0376/h, respectively.",Population pharmacokinetics of darbepoetin alpha in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18807251/),l,13.7,63373,DB00012,Darbepoetin alfa
,18807251,absorption rate constant,"The typical values of CL/f, V(1)/f, and absorption rate constant were 0.158 l/h, 13.7 l, and 0.0376/h, respectively.",Population pharmacokinetics of darbepoetin alpha in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18807251/),1/[h],0.0376,63374,DB00012,Darbepoetin alfa
,16554846,half-life of darbepoetin (t (1/2)),"The half-life of darbepoetin (t (1/2)) was 10.1 h (range 9.0-22.7 h), the volume of distribution was 0.77 l/kg (range 0.18-3.05 l/kg) and the clearance was 52.8 ml/h/kg (range 22.4-158.0 ml/h/kg).",Intravenous administration of darbepoetin to NICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16554846/),h,10.1,72200,DB00012,Darbepoetin alfa
,16554846,volume of distribution,"The half-life of darbepoetin (t (1/2)) was 10.1 h (range 9.0-22.7 h), the volume of distribution was 0.77 l/kg (range 0.18-3.05 l/kg) and the clearance was 52.8 ml/h/kg (range 22.4-158.0 ml/h/kg).",Intravenous administration of darbepoetin to NICU patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16554846/),[l] / [kg],0.77,72201,DB00012,Darbepoetin alfa
,16554846,clearance,"The half-life of darbepoetin (t (1/2)) was 10.1 h (range 9.0-22.7 h), the volume of distribution was 0.77 l/kg (range 0.18-3.05 l/kg) and the clearance was 52.8 ml/h/kg (range 22.4-158.0 ml/h/kg).",Intravenous administration of darbepoetin to NICU patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16554846/),[ml] / [h·kg],52.8,72202,DB00012,Darbepoetin alfa
,25996892,t(1/2),"Following the first Darbe dose at 2 and 10 μg/kg, t(1/2) was 24 and 32 h, and the area under the curve (AUC(inf)) was 26,555 and 180,886 h*mU/ml*, respectively.",Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25996892/),h,24,82543,DB00012,Darbepoetin alfa
,25996892,t(1/2),"Following the first Darbe dose at 2 and 10 μg/kg, t(1/2) was 24 and 32 h, and the area under the curve (AUC(inf)) was 26,555 and 180,886 h*mU/ml*, respectively.",Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25996892/),h,32,82544,DB00012,Darbepoetin alfa
,25996892,area under the curve (AUC(inf)),"Following the first Darbe dose at 2 and 10 μg/kg, t(1/2) was 24 and 32 h, and the area under the curve (AUC(inf)) was 26,555 and 180,886 h*mU/ml*, respectively.",Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25996892/),[h·mu] / [ml],"26,555",82545,DB00012,Darbepoetin alfa
,25996892,area under the curve (AUC(inf)),"Following the first Darbe dose at 2 and 10 μg/kg, t(1/2) was 24 and 32 h, and the area under the curve (AUC(inf)) was 26,555 and 180,886 h*mU/ml*, respectively.",Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25996892/),[h·mu] / [ml],"180,886",82546,DB00012,Darbepoetin alfa
,25996892,clearance,"In addition, clearance was not significantly different between the doses (0.05 and 0.04 l/h).",Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25996892/),[l] / [h],0.05,82547,DB00012,Darbepoetin alfa
,25996892,clearance,"In addition, clearance was not significantly different between the doses (0.05 and 0.04 l/h).",Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25996892/),[l] / [h],0.04,82548,DB00012,Darbepoetin alfa
,25996892,t(1/2),"At 7 d, t(1/2) was 26 and 35 h, and AUC(inf) was 10,790 and 56,233 h*mU/ml*, respectively (*P < 0.01).",Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25996892/),h,26,82549,DB00012,Darbepoetin alfa
,25996892,t(1/2),"At 7 d, t(1/2) was 26 and 35 h, and AUC(inf) was 10,790 and 56,233 h*mU/ml*, respectively (*P < 0.01).",Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25996892/),h,35,82550,DB00012,Darbepoetin alfa
,25996892,AUC(inf),"At 7 d, t(1/2) was 26 and 35 h, and AUC(inf) was 10,790 and 56,233 h*mU/ml*, respectively (*P < 0.01).",Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25996892/),[h·mu] / [ml],"10,790",82551,DB00012,Darbepoetin alfa
,25996892,AUC(inf),"At 7 d, t(1/2) was 26 and 35 h, and AUC(inf) was 10,790 and 56,233 h*mU/ml*, respectively (*P < 0.01).",Darbepoetin administration to neonates undergoing cooling for encephalopathy: a safety and pharmacokinetic trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25996892/),[h·mu] / [ml],"56,233",82552,DB00012,Darbepoetin alfa
,25466552,CE50,"Based on the sigmoid Emax model, the concentration producing 50% of the maximum erythropoietin effect is reported as CE50 = 0.41 ng/ml and the Hill coefficient as H = 3.0 for darbepoetin.",Pharmacokinetic and pharmacodynamic considerations on the erythropoietin effect and adverse events of darbepoetin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466552/),[ng] / [ml],0.41,93473,DB00012,Darbepoetin alfa
,25466552,Hill coefficient,"Based on the sigmoid Emax model, the concentration producing 50% of the maximum erythropoietin effect is reported as CE50 = 0.41 ng/ml and the Hill coefficient as H = 3.0 for darbepoetin.",Pharmacokinetic and pharmacodynamic considerations on the erythropoietin effect and adverse events of darbepoetin. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466552/),,3.0,93474,DB00012,Darbepoetin alfa
,25466552,CE05,"Accordingly, a pharmacodynamics-based threshold concentration can be estimated with CE05 = 0.153 ng/ml producing 5% of Emax and a ceiling concentration with CE95 = 1.098 ng/ml producing 95% of Emax, respectively.",Pharmacokinetic and pharmacodynamic considerations on the erythropoietin effect and adverse events of darbepoetin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466552/),[ng] / [ml],0.153,93475,DB00012,Darbepoetin alfa
,25466552,CE95,"Accordingly, a pharmacodynamics-based threshold concentration can be estimated with CE05 = 0.153 ng/ml producing 5% of Emax and a ceiling concentration with CE95 = 1.098 ng/ml producing 95% of Emax, respectively.",Pharmacokinetic and pharmacodynamic considerations on the erythropoietin effect and adverse events of darbepoetin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466552/),[ng] / [ml],1.098,93476,DB00012,Darbepoetin alfa
,25466552,elimination half-life,The time span associated with the concentration fluctuation between the ceiling and the threshold concentration is estimated with 236 h (= 2.84 times elimination half-life of 83 h) and shorter than the 336 h when dosing every other week.,Pharmacokinetic and pharmacodynamic considerations on the erythropoietin effect and adverse events of darbepoetin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466552/),h,83,93477,DB00012,Darbepoetin alfa
,25466552,elimination half-life,The time span associated with the concentration fluctuation between the ceiling and the threshold concentration is estimated with 236 h (= 2.84 times elimination half-life of 83 h) and shorter than the 336 h when dosing every other week.,Pharmacokinetic and pharmacodynamic considerations on the erythropoietin effect and adverse events of darbepoetin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/25466552/),h,33,93478,DB00012,Darbepoetin alfa
,16485917,volumes of distribution,"Darbepoetin alfa exhibited limited extravascular distribution after IV administration, with both initial and steady-state mean volumes of distribution (36.1 mL/kg and 55.2 mL/kg, respectively, after a single IV dose) approximating the plasma volume.",Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16485917/),[ml] / [kg],36.1,108848,DB00012,Darbepoetin alfa
,16485917,volumes of distribution,"Darbepoetin alfa exhibited limited extravascular distribution after IV administration, with both initial and steady-state mean volumes of distribution (36.1 mL/kg and 55.2 mL/kg, respectively, after a single IV dose) approximating the plasma volume.",Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16485917/),[ml] / [kg],55.2,108849,DB00012,Darbepoetin alfa
,16485917,clearance,"After a single IV dose, darbepoetin alfa exhibited a mean clearance of 1.05 mL/h/kg, with a mean terminal half-life of 38.8 hours.",Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16485917/),[ml] / [h·kg],1.05,108850,DB00012,Darbepoetin alfa
,16485917,terminal half-life,"After a single IV dose, darbepoetin alfa exhibited a mean clearance of 1.05 mL/h/kg, with a mean terminal half-life of 38.8 hours.",Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16485917/),h,38.8,108851,DB00012,Darbepoetin alfa
,16485917,terminal half-life,"Darbepoetin alfa is cleared slowly after IV administration to patients with cancer receiving chemotherapy, resulting in a terminal half-life of 38.8 hours.",Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16485917/),h,38.8,108852,DB00012,Darbepoetin alfa
,17178635,half-lives,"The half-lives of immunoreactive radioactivity in the terminal phase after intravenous and subcutaneous administration were 14.05 and 14.36 h, respectively, and the bioavailability rate after subcutaneous administration was 47%.","Pharmacokinetic study of darbepoetin alfa: absorption, distribution, and excretion after a single intravenous and subcutaneous administration to rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178635/),h,14.05,128274,DB00012,Darbepoetin alfa
,17178635,half-lives,"The half-lives of immunoreactive radioactivity in the terminal phase after intravenous and subcutaneous administration were 14.05 and 14.36 h, respectively, and the bioavailability rate after subcutaneous administration was 47%.","Pharmacokinetic study of darbepoetin alfa: absorption, distribution, and excretion after a single intravenous and subcutaneous administration to rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178635/),h,14.36,128275,DB00012,Darbepoetin alfa
,17178635,bioavailability rate,"The half-lives of immunoreactive radioactivity in the terminal phase after intravenous and subcutaneous administration were 14.05 and 14.36 h, respectively, and the bioavailability rate after subcutaneous administration was 47%.","Pharmacokinetic study of darbepoetin alfa: absorption, distribution, and excretion after a single intravenous and subcutaneous administration to rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178635/),%,47,128276,DB00012,Darbepoetin alfa
,17178635,excretion ratios,The excretion ratios of radioactivity into urine and faeces up to 168 h were 71.4 and 14.1% after the intravenous administration and 74.9 and 12.0% after the subcutaneous administration.,"Pharmacokinetic study of darbepoetin alfa: absorption, distribution, and excretion after a single intravenous and subcutaneous administration to rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178635/),%,71.4,128277,DB00012,Darbepoetin alfa
,17178635,excretion ratios,The excretion ratios of radioactivity into urine and faeces up to 168 h were 71.4 and 14.1% after the intravenous administration and 74.9 and 12.0% after the subcutaneous administration.,"Pharmacokinetic study of darbepoetin alfa: absorption, distribution, and excretion after a single intravenous and subcutaneous administration to rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178635/),%,14.1,128278,DB00012,Darbepoetin alfa
,17178635,excretion ratios,The excretion ratios of radioactivity into urine and faeces up to 168 h were 71.4 and 14.1% after the intravenous administration and 74.9 and 12.0% after the subcutaneous administration.,"Pharmacokinetic study of darbepoetin alfa: absorption, distribution, and excretion after a single intravenous and subcutaneous administration to rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178635/),%,74.9,128279,DB00012,Darbepoetin alfa
,17178635,excretion ratios,The excretion ratios of radioactivity into urine and faeces up to 168 h were 71.4 and 14.1% after the intravenous administration and 74.9 and 12.0% after the subcutaneous administration.,"Pharmacokinetic study of darbepoetin alfa: absorption, distribution, and excretion after a single intravenous and subcutaneous administration to rats. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17178635/),%,12.0,128280,DB00012,Darbepoetin alfa
,25989868,Clearance,"Clearance and volume of distribution were estimated as 0.0465 L/h (95% confidence interval 0.0392-0.0537) and 1.58 L (95% confidence interval 1.29-1.87), respectively.",Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25989868/),[l] / [h],0.0465,145556,DB00012,Darbepoetin alfa
,25989868,volume of distribution,"Clearance and volume of distribution were estimated as 0.0465 L/h (95% confidence interval 0.0392-0.0537) and 1.58 L (95% confidence interval 1.29-1.87), respectively.",Population Pharmacokinetics of Darbepoetin Alfa in Conjunction with Hypothermia for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25989868/),l,1.58,145557,DB00012,Darbepoetin alfa
,11308269,T(max),"After a single dose during chemotherapy cycle 1, pharmacokinetic parameters (mean (SD), n) for the first 15 patients were: T(max)86.1 (22.8) h (n = 14); C(max)9.0 (5.1) ng ml(-1)(n = 14); t(1/2,z)32.6 (11.8) h (n = 7); CL/F 3.7 (1.0) ml h(-1) kg(-1)(n = 7).",Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11308269/),h,86.1,145997,DB00012,Darbepoetin alfa
,11308269,C(max),"After a single dose during chemotherapy cycle 1, pharmacokinetic parameters (mean (SD), n) for the first 15 patients were: T(max)86.1 (22.8) h (n = 14); C(max)9.0 (5.1) ng ml(-1)(n = 14); t(1/2,z)32.6 (11.8) h (n = 7); CL/F 3.7 (1.0) ml h(-1) kg(-1)(n = 7).",Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11308269/),[ng] / [ml],9.0,145998,DB00012,Darbepoetin alfa
,11308269,"t(1/2,z)","After a single dose during chemotherapy cycle 1, pharmacokinetic parameters (mean (SD), n) for the first 15 patients were: T(max)86.1 (22.8) h (n = 14); C(max)9.0 (5.1) ng ml(-1)(n = 14); t(1/2,z)32.6 (11.8) h (n = 7); CL/F 3.7 (1.0) ml h(-1) kg(-1)(n = 7).",Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11308269/),h,32.6,145999,DB00012,Darbepoetin alfa
,11308269,CL/F,"After a single dose during chemotherapy cycle 1, pharmacokinetic parameters (mean (SD), n) for the first 15 patients were: T(max)86.1 (22.8) h (n = 14); C(max)9.0 (5.1) ng ml(-1)(n = 14); t(1/2,z)32.6 (11.8) h (n = 7); CL/F 3.7 (1.0) ml h(-1) kg(-1)(n = 7).",Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11308269/),[ml] / [h·kg],3.7,146000,DB00012,Darbepoetin alfa
,17526547,terminal half-life,Pharmacokinetic investigations of darbepoetin alfa using prolonged blood sampling times established that the mean terminal half-life after subcutaneous (SC) administration is 70 to 105 hours.,Pharmacology of darbepoetin alfa. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17526547/),h,70 to 105,151870,DB00012,Darbepoetin alfa
,16640455,terminal half-life,The mean terminal half-life in serum of darbepoetin alfa was determined to be 69.6 hours.,An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640455/),h,69.6,164244,DB00012,Darbepoetin alfa
,16640455,apparent clearance,"Peak serum concentrations were reached in a median time of 36 hours postdose, and a mean apparent clearance of 3.51 mL/h/kg was comparable to that observed previously in this patient population.",An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640455/),[ml] / [h·kg],3.51,164245,DB00012,Darbepoetin alfa
,16640455,terminal half-life,"Based on an extended sampling schedule of 4 weeks, the terminal half-life of darbepoetin alfa was approximately 70 hours.",An extended terminal half-life for darbepoetin alfa: results from a single-dose pharmacokinetic study in patients with chronic kidney disease not receiving dialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16640455/),h,70,164246,DB00012,Darbepoetin alfa
less,19414943,half-life,"Only 81 (57%) respondents believed that the half-life of the short-acting ESAs is less than one day, 67 (46.9%) believed the half-life of darbepoetin is 2-4 days, and 52 (36.6%) believed the half-life of CERA is 5-10 days; 79 (55.6%) respondents believed that the interval of dosing of darbepoetin is once biweekly, and 92 (71.9%) believed that the interval of dosing of CERA is once a month.",Survey of attitude of physicians on updates in the management of anemia in chronic kidney disease patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19414943/),d,one,167132,DB00012,Darbepoetin alfa
,19414943,half-life,"Only 81 (57%) respondents believed that the half-life of the short-acting ESAs is less than one day, 67 (46.9%) believed the half-life of darbepoetin is 2-4 days, and 52 (36.6%) believed the half-life of CERA is 5-10 days; 79 (55.6%) respondents believed that the interval of dosing of darbepoetin is once biweekly, and 92 (71.9%) believed that the interval of dosing of CERA is once a month.",Survey of attitude of physicians on updates in the management of anemia in chronic kidney disease patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19414943/),d,2-4,167133,DB00012,Darbepoetin alfa
,19414943,half-life,"Only 81 (57%) respondents believed that the half-life of the short-acting ESAs is less than one day, 67 (46.9%) believed the half-life of darbepoetin is 2-4 days, and 52 (36.6%) believed the half-life of CERA is 5-10 days; 79 (55.6%) respondents believed that the interval of dosing of darbepoetin is once biweekly, and 92 (71.9%) believed that the interval of dosing of CERA is once a month.",Survey of attitude of physicians on updates in the management of anemia in chronic kidney disease patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19414943/),d,5-10,167134,DB00012,Darbepoetin alfa
,24504705,area under the concentration-time curve from time zero to infinity (AUC0-∞),"When administered intravenously, the area under the concentration-time curve from time zero to infinity (AUC0-∞), clearance (CL) and terminal half-life (t 1/2) of DA were 263.7 ng · h/mL, 1.77 mL/h/kg and 26.25 h, respectively (mean).","Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504705/),[h·ng] / [ml],263.7,173033,DB00012,Darbepoetin alfa
,24504705,clearance (CL),"When administered intravenously, the area under the concentration-time curve from time zero to infinity (AUC0-∞), clearance (CL) and terminal half-life (t 1/2) of DA were 263.7 ng · h/mL, 1.77 mL/h/kg and 26.25 h, respectively (mean).","Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504705/),[ml] / [h·kg],1.77,173034,DB00012,Darbepoetin alfa
,24504705,terminal half-life (t 1/2),"When administered intravenously, the area under the concentration-time curve from time zero to infinity (AUC0-∞), clearance (CL) and terminal half-life (t 1/2) of DA were 263.7 ng · h/mL, 1.77 mL/h/kg and 26.25 h, respectively (mean).","Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504705/),h,26.25,173035,DB00012,Darbepoetin alfa
,24504705,AUC0-∞,"In patients under 12 years old, AUC0-∞, CL and t 1/2 were 219.1 ng · h/mL, 2.19 mL/h/kg, 23.62 h, respectively.","Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504705/),[h·ng] / [ml],219.1,173036,DB00012,Darbepoetin alfa
,24504705,CL,"In patients under 12 years old, AUC0-∞, CL and t 1/2 were 219.1 ng · h/mL, 2.19 mL/h/kg, 23.62 h, respectively.","Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504705/),[ml] / [h·kg],2.19,173037,DB00012,Darbepoetin alfa
,24504705,t 1/2,"In patients under 12 years old, AUC0-∞, CL and t 1/2 were 219.1 ng · h/mL, 2.19 mL/h/kg, 23.62 h, respectively.","Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504705/),h,23.62,173038,DB00012,Darbepoetin alfa
,24504705,time to reach maximum concentration (t max),"When administered subcutaneously, time to reach maximum concentration (t max) and maximum concentration (C max) were 24.47 h and 1.704 ng/mL, and AUC0-∞, apparent clearance (CL/F) and t 1/2 were 141.1 ng · h/mL, 3.23 mL/h/kg and 46.73 h, respectively.","Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504705/),h,24.47,173039,DB00012,Darbepoetin alfa
,24504705,maximum concentration (C max),"When administered subcutaneously, time to reach maximum concentration (t max) and maximum concentration (C max) were 24.47 h and 1.704 ng/mL, and AUC0-∞, apparent clearance (CL/F) and t 1/2 were 141.1 ng · h/mL, 3.23 mL/h/kg and 46.73 h, respectively.","Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504705/),[h·ng] / [ml],141.1,173040,DB00012,Darbepoetin alfa
,24504705,AUC0-∞,"When administered subcutaneously, time to reach maximum concentration (t max) and maximum concentration (C max) were 24.47 h and 1.704 ng/mL, and AUC0-∞, apparent clearance (CL/F) and t 1/2 were 141.1 ng · h/mL, 3.23 mL/h/kg and 46.73 h, respectively.","Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504705/),[h·ng] / [ml],141.1,173041,DB00012,Darbepoetin alfa
,24504705,apparent clearance (CL/F),"When administered subcutaneously, time to reach maximum concentration (t max) and maximum concentration (C max) were 24.47 h and 1.704 ng/mL, and AUC0-∞, apparent clearance (CL/F) and t 1/2 were 141.1 ng · h/mL, 3.23 mL/h/kg and 46.73 h, respectively.","Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504705/),[ml] / [h·kg],3.23,173042,DB00012,Darbepoetin alfa
,24504705,t 1/2,"When administered subcutaneously, time to reach maximum concentration (t max) and maximum concentration (C max) were 24.47 h and 1.704 ng/mL, and AUC0-∞, apparent clearance (CL/F) and t 1/2 were 141.1 ng · h/mL, 3.23 mL/h/kg and 46.73 h, respectively.","Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504705/),h,46.73,173043,DB00012,Darbepoetin alfa
,24504705,t max,"In patients under 12 years old, t max and C max were 7.50 h and 2.053 ng/mL, and AUC0-∞, CL/F and t 1/2 were 136.7 ng · h/mL, 3.29 mL/h/kg and 37.75 h, respectively, which was higher in C max, faster in t max and shorter t 1/2 compared to adult CKD patients, while AUC was not obviously different.","Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504705/),h,7.50,173044,DB00012,Darbepoetin alfa
,24504705,C max,"In patients under 12 years old, t max and C max were 7.50 h and 2.053 ng/mL, and AUC0-∞, CL/F and t 1/2 were 136.7 ng · h/mL, 3.29 mL/h/kg and 37.75 h, respectively, which was higher in C max, faster in t max and shorter t 1/2 compared to adult CKD patients, while AUC was not obviously different.","Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504705/),[h·ng] / [ml],136.7,173045,DB00012,Darbepoetin alfa
,24504705,AUC0-∞,"In patients under 12 years old, t max and C max were 7.50 h and 2.053 ng/mL, and AUC0-∞, CL/F and t 1/2 were 136.7 ng · h/mL, 3.29 mL/h/kg and 37.75 h, respectively, which was higher in C max, faster in t max and shorter t 1/2 compared to adult CKD patients, while AUC was not obviously different.","Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504705/),[h·ng] / [ml],136.7,173046,DB00012,Darbepoetin alfa
,24504705,CL/F,"In patients under 12 years old, t max and C max were 7.50 h and 2.053 ng/mL, and AUC0-∞, CL/F and t 1/2 were 136.7 ng · h/mL, 3.29 mL/h/kg and 37.75 h, respectively, which was higher in C max, faster in t max and shorter t 1/2 compared to adult CKD patients, while AUC was not obviously different.","Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504705/),[ml] / [h·kg],3.29,173047,DB00012,Darbepoetin alfa
,24504705,t 1/2,"In patients under 12 years old, t max and C max were 7.50 h and 2.053 ng/mL, and AUC0-∞, CL/F and t 1/2 were 136.7 ng · h/mL, 3.29 mL/h/kg and 37.75 h, respectively, which was higher in C max, faster in t max and shorter t 1/2 compared to adult CKD patients, while AUC was not obviously different.","Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24504705/),h,37.75,173048,DB00012,Darbepoetin alfa
,16939525,relative bioavailability,"Modelling indicated that for a 70-kg human, the observed nearly twofold disproportionate dose-exposure relationship at the 8.0 microg kg(-1)-dose relative to the 0.75 microg kg(-1)-dose may reflect changing relative bioavailability, which increased from approximately 48% at 0.75 microg kg(-1) to 78% at 8.0 microg kg(-1).",Population pharmacokinetics of darbepoetin alfa in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16939525/),%,48,180205,DB00012,Darbepoetin alfa
,16939525,relative bioavailability,"Modelling indicated that for a 70-kg human, the observed nearly twofold disproportionate dose-exposure relationship at the 8.0 microg kg(-1)-dose relative to the 0.75 microg kg(-1)-dose may reflect changing relative bioavailability, which increased from approximately 48% at 0.75 microg kg(-1) to 78% at 8.0 microg kg(-1).",Population pharmacokinetics of darbepoetin alfa in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16939525/),%,78,180206,DB00012,Darbepoetin alfa
,21046285,terminal half-life,The PK profile was dose-proportional over the dose range tested; terminal half-life of AMG 114 was approximately 130 h.,Phase I/II randomised study of a novel erythropoiesis-stimulating agent (AMG 114) for the treatment of anaemia with concomitant chemotherapy in patients with non-myeloid malignancies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21046285/),h,130,212891,DB00012,Darbepoetin alfa
,17120240,peak serum concentration,"After a single dose of darbepoetin alfa, the mean (SD) peak serum concentration was 10.5 (3) ng/ml, and the median time to peak concentration was 71.4 hr.",Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17120240/),[ng] / [ml],10.5,213212,DB00012,Darbepoetin alfa
,17120240,time to peak concentration,"After a single dose of darbepoetin alfa, the mean (SD) peak serum concentration was 10.5 (3) ng/ml, and the median time to peak concentration was 71.4 hr.",Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17120240/),h,71.4,213213,DB00012,Darbepoetin alfa
,17120240,terminal half-life,Darbepoetin alfa exhibited a mean (SD) terminal half-life of 49.4 (32) hr.,Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17120240/),h,49.4,213214,DB00012,Darbepoetin alfa
,11402086,elimination half-life,"Thus, following intravenous administration, the mean elimination half-life of NESP is 25.3 vs 8.5 h for rHuEPO.",An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402086/),h,25.3,216401,DB00012,Darbepoetin alfa
,11402086,elimination half-life,"Thus, following intravenous administration, the mean elimination half-life of NESP is 25.3 vs 8.5 h for rHuEPO.",An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402086/),h,8.5,216402,DB00012,Darbepoetin alfa
,11402086,terminal half-life,"After subcutaneous administration, the mean terminal half-life for NESP is 48.8 h.",An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402086/),h,48.8,216403,DB00012,Darbepoetin alfa
,11402086,bioavailability,"The mean bioavailability of NESP after subcutaneous administration is approximately 37%, similar to that reported for rHuEPO.",An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402086/),%,37,216404,DB00012,Darbepoetin alfa
,12126221,terminal half-life,"The agent often has to be administered 2-3 times/week for maximum efficacy A new product, darbepoetin-alpha, is a hyperglycosylated erythropoiesis-stimulating protein that has a longer terminal half-life than rHuEPO (25.3 vs 8.5 hrs), which allows for less frequent dosing.",Darbepoetin-alpha: a review of the literature. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12126221/),h,25.3,225069,DB00012,Darbepoetin alfa
,12126221,terminal half-life,"The agent often has to be administered 2-3 times/week for maximum efficacy A new product, darbepoetin-alpha, is a hyperglycosylated erythropoiesis-stimulating protein that has a longer terminal half-life than rHuEPO (25.3 vs 8.5 hrs), which allows for less frequent dosing.",Darbepoetin-alpha: a review of the literature. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12126221/),h,8.5,225070,DB00012,Darbepoetin alfa
,16044026,bioavailability,"Darbepoetin alfa (0.75 microg/kg SC) pharmacokinetics were similar in CHF patients and healthy subjects, with a mean (+/-SD) bioavailability of 29 (+/-11)% and 37 (+/-8)%, respectively.",Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044026/),%,29,229135,DB00012,Darbepoetin alfa
,16044026,bioavailability,"Darbepoetin alfa (0.75 microg/kg SC) pharmacokinetics were similar in CHF patients and healthy subjects, with a mean (+/-SD) bioavailability of 29 (+/-11)% and 37 (+/-8)%, respectively.",Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044026/),%,37,229136,DB00012,Darbepoetin alfa
,12432437,clearance,"After IV administration, the mean clearance of darbepoetin alfa was 2.3 ml/h per kg, with a mean terminal half-life of 22.1 h.",Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12432437/),[ml] / [h·kg],2.3,255000,DB00012,Darbepoetin alfa
,12432437,terminal half-life,"After IV administration, the mean clearance of darbepoetin alfa was 2.3 ml/h per kg, with a mean terminal half-life of 22.1 h.",Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12432437/),h,22.1,255001,DB00012,Darbepoetin alfa
,12432437,terminal half-life,"After SC administration, absorption was rate limiting, with a mean terminal half-life of 42.8 h and a mean bioavailability of 54%.",Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12432437/),h,42.8,255002,DB00012,Darbepoetin alfa
,12432437,bioavailability,"After SC administration, absorption was rate limiting, with a mean terminal half-life of 42.8 h and a mean bioavailability of 54%.",Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12432437/),%,54,255003,DB00012,Darbepoetin alfa
